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Background: Exposure to perfluorooctane sulfonic acid (PFOS) or to perfluorooctanoic acid
(PFOA) increases mouse and human peroxisome proliferator–activated receptor alpha (PPARα)
subtype activity, which influences lipid metabolism. Because cholesterol is the substrate from which
testosterone is synthesized, exposure to these substances has the potential to alter testosterone
concentrations.
Objectives: We explored associations of total testosterone and sex hormone–binding globulin
(SHBG) concentrations at age 15 years with prenatal exposures to PFOS, PFOA, perfluorohexane
sulfonic acid (PFHxS), and perfluoronanoic acid (PFNA) in females.
Methods: Prenatal concentrations of the perfluoroalkyl acids (PFAAs) were measured in serum
collected from pregnant mothers at enrollment (1991–1992) in the Avon Longitudinal Study of
Parents and Children (ALSPAC). The median gestational age when the maternal blood sample was
obtained was 16 weeks (interquartile range, 11–28 weeks). Total testosterone and SHBG concentrations were measured in serum obtained from their daughters at 15 years of age. Associations
between prenatal PFAAs concentrations and reproductive outcomes were estimated using linear
regression models (n = 72).
Results: Adjusted total testosterone concentrations were on average 0.18-nmol/L (95% CI:
0.01, 0.35) higher in daughters with prenatal PFOS in the upper concentration tertile compared
with daughters with prenatal PFOS in the lower tertile. Adjusted total testosterone concentrations
were also higher in daughters with prenatal concentrations of PFOA (β = 0.24; 95% CI: 0.05, 0.43)
and PFHxS (β = 0.18; 95% CI: 0.00, 0.35) in the upper tertile compared with daughters with
concentrations in the lower tertile. We did not find evidence of associations between PFNA and
total testosterone or between any of the PFAAs and SHBG.
Conclusions: Our findings were based on a small study sample and should be interpreted with
caution. However, they suggest that prenatal exposure to some PFAAs may alter testosterone
concentrations in females.
C itation : Maisonet M, Calafat AM, Marcus M, Jaakkola JJ, Lashen H. 2015. Prenatal
exposure to perfluoroalkyl acids and serum testosterone concentrations at 15 years of age in
female ALSPAC study participants. Environ Health Perspect 123:1325–1330; http://dx.doi.
org/10.1289/ehp.1408847

Introduction
Perfluoroalkyl acids (PFAAs) constitute a class
of synthetic chemicals whose water and oil
repellency and surfactant properties have useful
applications in a wide range of industrial and
commercial products (Lindstrom et al. 2011).
Some PFAAs are persistent and ubiquitous in
the environment, and can be found in higher
concentrations at higher levels in the food
chain (Stockholm Convention 2014). Human
exposure to PFAAs is common (Joensen et al.
2013; Kato et al. 2011). Detectable concentrations of some PFAAs in cord blood (Apelberg
et al. 2007) and amniotic fluid from pregnant
women (Stein et al. 2012) suggest human
fetal exposure.
Effects of endocrine disruptors on reproduction may originate during the fetal stage
(Crain et al. 2008), yet current knowledge
on whether prenatal exposures to PFAAs can
have an impact on human reproduction is
limited to few studies. A longitudinal study of
young adult females investigated associations
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of prenatal exposure to perfluoroo ctanoic
acid (PFOA) and perfluorooctane sulfonic
acid (PFOS) on menstrual characteristics,
reproductive hormone levels, and number of
follicles (Kristensen et al. 2013). In this study
prenatal exposure to perfluorooctanoic acid
(PFOA) was associated with delayed menarche
attainment but not with other markers of
reproductive function, whereas prenatal
exposure to PFOS was not associated with any
of the study outcomes (Kristensen et al. 2013).
A nested case–control study conducted by our
group explored the role of prenatal exposure to
PFAAs on timing of menarche (Christensen
et al. 2011). We did not find evidence of an
association between prenatal exposure to the
PFAAs tested and earlier menarche attainment.
Last, a study of young adults explored whether
prenatal PFOA or PFOS exposure was associated with semen quality, testicular volume, and
reproductive hormone levels. Inverse associations of sperm concentration and total sperm
count and positive associations of luteinizing
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and follicle-stimulating hormone with prenatal
PFOA exposure were observed (Vested et al.
2013). To our knowledge, studies exploring
effects of prenatal exposures to PFAAs on
hormone concentrations in experimental
animals have not been conducted.
Reproductive effects of many endocrine disruptors are thought to be mediated
mainly by agonistic or antagonistic nuclear
sex hormone receptor processes (Crain et al.
2008). It would appear, however, that PFAAs
could impair human reproduction through
other pathways. For instance, some PFAAs
are known to increase mouse and human
peroxisome proliferator–activated receptor
alpha (PPARα) subtype activity (Takacs
and Abbott 2007; Wolf et al. 2008), which
influences lipid metabolism. Positive associations between exposure to PFAAs and lipids
have been noted in adolescents and pregnant
women from population-based cross-sectional
epidemiologic reports (Geiger et al. 2014;
Starling et al. 2014). Because cholesterol
is the substrate from which reproductive
hormones are synthesized (Burger 2002),
exposure to PFAAs have the potential to
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alter concentrations of bioavailable circulating hormones. Alternatively, there is some
evidence that endocrine disruptors, including
PFOS, bind to sex hormone–binding globulin
(SHBG) (Jones et al. 2003), and displacement of reproductive hormones from SHBG
binding sites could alter bioavailability of
circulating hormones (Déchaud et al. 1999).
High serum testosterone concentrations in
females are a main feature of polycystic ovary
syndrome (PCOS) that is associated with
disruption of reproductive function (Azziz
et al. 2009) as well as long-term sequelae such
as metabolic disorders (Apridonidze et al.
2005) and possibly increased cardiovascular
disease risk (Cibula et al. 2000). We report
results of a study conducted to explore associations of prenatal exposures to PFOS, PFOA,
perfluorohexane sulfonic acid (PFHxS), and
perfluoronanoic acid (PFNA) with testosterone and SHBG serum concentrations at
15 years of age in females enrolled in the Avon
Longitudinal Study of Parents and Children
(ALSPAC). This study focused on female
participants because data on prenatal PFAAs
exposure in males enrolled in the ALSPAC are
not yet available for analyses.

Methods
Source population. The ALSPAC study
enrolled pregnant women from three
health districts of the old administrative
county of Avon, United Kingdom, with an
expected delivery date between April 1991
and December 1992. A total of 14,541
pregnant women, approximately 72% of the
eligible source population, enrolled in the
cohort during the 1990–1992 recruitment
campaign. Details of recruitment methods are
described elsewhere (Boyd et al. 2013).
Study population. We linked concentrations of PFAAs measured in enrolled
pregnant women with their daughters’ serum
concentrations of total testosterone and
SHBG measured at 15 years of age using
data from two separate investigations previously conducted on the ALSPAC. Maternal
concentrations of PFAAs were measured in
banked blood for a nested case–control study
of prenatal exposures to PFAAs and menarche
in daughters (Christensen et al. 2011). The
median gestational age when maternal blood
samples were obtained was 16 weeks [interquartile range (IQR), 11–28 weeks]. Total
testosterone and SHBG concentrations were
measured in serum samples collected from the
1,790 adolescent females who participated in
the 15-years clinic visit open to all members of
the ALSPAC cohort.
Cases in the nested case–control study
consisted of 218 daughters who attained
menarche at < 11.5 years and controls were a
random sample of 230 daughters who attained
menarche at ≥ 11.5 years of age (Christensen
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et al. 2011). We restricted the present study to
daughters from the control sample (n = 230)
because these are representative of the range
of ages when menarche is most commonly
attained. Not everyone who participated in
the 15-years clinic visit had been a part of the
case–control study; thus, after linkage of the
230 controls with the 1,790 clinic participants, only 72 females had prenatal concentrations of PFAAs and serum testosterone and
SHBG concentrations at age 15 years available
for the analyses.
Covariates. Covariates were selected
a priori. Maternal covariates considered in the
analyses were maternal smoking during pregnancy (yes, no); age at delivery (years); and
prepregnancy body mass index (BMI; kilograms per meter squared) (Ernst et al. 2012;
Sowers et al. 2001). Maternal educational level
was also included in the set of maternal covariates as a measure of socioeconomic status
(lowest: none/Certification of Secondary
Education or Vocational; middle: Ordinary
Level; highest: Advanced Level or University
Degree). An Ordinary Level education is the
qualification obtained at age 16 years when
obligatory schooling ends, and an Advanced
Level education is secondary or pre-university
education certification. Daughters’ covariates
considered in the analyses were serum SHBG
concentrations at 15 years (nanomoles per
liter), BMI at 15 years, age at menarche (< 12,
12–13, 14 years), and time of day the blood
sample for testosterone testing was obtained
(Ankarberg and Norjavaara 1999; Brand
et al. 2011). Daughters’ BMI at age 15 years
and age at menarche were also considered as
covariates for the analyses for SHBG. There is
a possibility that daughter’s BMI at 15 years
might be affected by total testosterone and
SHBG serum concentrations at 15 years or
that daughter’s age at menarche might be
affected by total testosterone serum concentrations. In such circumstances, use of BMI at
15 years or of age at menarche as covariates
would be unnecessary. Data collection instruments and study variables have been described
in detail elsewhere (ALSPAC 2014; Fraser
et al. 2013).
Laboratory analyses. One total testosterone and one SHBG measure was made on
serum samples obtained from daughters at
age 15 years. About half of the blood samples
were drawn between 0800 and 0900 hours
and the other half between 1200 and 1500
hours. Total testosterone was measured using
Agilent triple quadrupole 6410 liquid chromatography/mass spectrometry equipment with
an electrospray ionization source operating
in positive ion mode (Agilent Technologies,
Wilmington, DE, USA). Multiple reaction
monitoring was used to quantify total
testosterone by using trideuterated testosterone (d3t-testosterone), with the following
volume

transitions: m/z 289.2-97 and 289.2-109 for
testosterone and 292.2-97 and 292.2-109 for
d3t-testosterone. The coefficients of variation of the method were 5.3, 1.6, and 1.2%
for testosterone at 0.6, 6.6, and 27.7 nmol/L
respectively. In an adult female population,
the total testosterone reference range of 0.27–
1.56 nmol/L has been suggested for measurements obtained by liquid chromatography/
mass spectrometry (Kane et al. 2007). SHBG
was measured using a Cobas Auto Analyzer
(Roche Diagnostic, West Sussex, UK) and
SHBG reagent using the manufacturer’s
calibrators and quality control material.
PFOS, PFOA, PFHxS, and PFNA were
measured in stored maternal sera collected
during 1991–1992 at pregnancy. The median
gestational age when samples were obtained
was 15 weeks and the IQR was 10–28 weeks.
Serum was analyzed using online phase
extraction–high performance liquid chromatography–isotope dilution tandem mass spectrometry as described elsewhere (Kuklenyik
et al. 2005). Limits of detection (LOD) were
0.2 ng/mL (PFOS), 0.1 ng/mL (PFOA,
PFHxS), and 0.082 ng/mL (PFNA). A correction factor of 0.82 was applied to the PFNA
concentrations to adjust for the purity of the
analytic standards used [Centers for Disease
Control and Prevention (CDC) 2013]. The
precision of measurements, expressed as the
relative standard deviation, was 8–13%,
depending on the analyte. Prenatal concentrations of all PFAA analytes measured
in the study group were above the LOD.
Low-concentration (~ 2–9 ng/mL) and highconcentration (~ 6–25 ng/mL) quality control
(QC) materials prepared with pooled serum
were analyzed with standards, reagent blanks,
and study samples. The concentrations of the
QCs and blanks were evaluated using standard
statistical probability rules.
Statistical analyses. Means of study
outcomes by tertiles of prenatal PFAAs
concentrations exhibited equal variances (data
not shown). The null hypothesis for homogeneity of variances was tested separately for
either total testosterone or SHBG concentrations with each prenatal PFAA using the
Bartlett test, and none rejected at p < 0.05.
We used generalized additive models to
detect whether associations between prenatal
PFAA concentrations and the study outcomes
exhibited departures from linearity (Hastie
and Tibshirani 1987). We fitted these models
with a smooth term for the continuous
PFAAs for each prenatal PFAA and daughter’s
outcomes combination separately. All smooth
terms were fitted with 3 degrees of freedom.
Chi-square tests from analyses of deviance
comparing models with and without the
smooth exposure term were performed, and
no statistical departures from linearity were
apparent at a p < 0.05 level of significance.
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For analyses of prenatal continuous
PFAAs, we estimated associations with total
testosterone concentrations before and after
exclusion of influential data points. We
used studentized residuals (> 2.5 or < –2.5),
leverage [>(2 number of predictor+2)/n],
Cook’s distance (> 4/n), and visual observation
of scatter plots as diagnostic tools to identify
influential data points. After applying these
criteria, two data points with corresponding
values of PFOS of 66.4 and 69.2 ng/mL;
two data points with corresponding values of
PFOA of 13.8 and 14.6 ng/mL; three data
points with corresponding values of PFHxS
of 17.5, 49.8, and 54.1 ng/mL; and three data
points with corresponding values of PFNA of
0.98, 1.07, and 1.15 ng/mL were excluded
from respective models. It is important to
underscore that influential data points identified using statistical methods do exhibit values
of PFAAs concentrations observed in the
human populations.
We report results from three separate linear
regression models for the associations between
the study outcomes and each PFAA: a) unadjusted model, b) fully adjusted, c) adjusted only
by the covariates that were associated with the
model’s respective PFAA at p < 0.20.
Human subject protection was assessed
and approved by the ALSPAC Law and Ethics
Committee and the Local Research Ethics
Committees. Collection of pubertal data
was also approved by the CDC Institutional
Review Board. Human participants gave
written informed consent before enrollment in
the ALSPAC. Parental consent was obtained
at the 15-years clinic visit because daughters
were underage. Daughters could refuse any
procedure requiring consent at any time
during the clinic visit.

Results
PFOS showed the highest median prenatal
concentration (19.2 ng/mL) followed by
PFOA (3.6 ng/mL), PFHxS (1.6 ng/mL),
and PFNA (0.5 ng/mL) (Table 1). Spearman
correlation coefficients suggest a moderate
level of correlation between PFAAs: r values
ranged between 0.47 and 0.65 (plots not
shown). Median serum concentrations of
total testosterone and SHBG in daughters at

15 years were 0.8 and 52.1 nmol/L, respectively (Table 1). The Pearson correlation coefficient between serum total testosterone and
SHBG suggests a weak correlation (r = 0.11)
between these two variables (plot not shown).
The age range of the daughters in our study
group was 15.0–15.9 years. All daughters had
attained menarche and none used hormonal
contraception. More than 50% of mothers
reported having an advanced level or university
degree education and delivering her daughter
at ≥ 30 years of age. All of the mothers were
of white race and had, on average, a normal
prepregnancy weight (Table 2). Scatter
plots for total testosterone concentrations
in 15-year-old daughters by prenatal PFOS,
PFOA, PFHxS, and PFNA serum concentrations with unadjusted linear regression line
(Figure 1) suggest higher total testosterone
serum concentrations with increasing values
of prenatal PFAAs concentrations. There is
also a suggestion of outlying values for PFOA,
PFOS, and PFHxS.
Given the size of the study group,
we created two adjusted models to determine associations between the outcomes
and each prenatal PFAA separately. One
adjusted model, which we refer to as the
fully adjusted model, included all covariates
identified a priori. The other, which we refer
to as the parsimonious model, included only
those covariates associated with the model’s
corresponding PFAA at p < 0.20. In the
fully adjusted linear regression model, total
testosterone concentrations were on average
0.18-nmol/L [95% confidence interval
(CI) = 0.01, 0.35] higher in the group of
daughters with prenatal PFOS concentrations
in the upper exposure tertile compared with
the group of daughters with prenatal PFOS
in the lower tertile (Table 3). This result was
similar to that of the unadjusted PFOS model.
In addition, none of the covariates were associated with prenatal PFOS at a chi-square
p-value < 0.20; therefore, the parsimonious
model is the same as the unadjusted model.
Similar patterns were observed for PFOA
(β = 0.24; 95% CI: 0.05, 0.43) and PFHxS
(β = 0.18; 95% CI: 0.00, 0.35), where total
testosterone levels in fully adjusted models were
on average higher in the group of daughters

Table 1. Distribution of PFAAs concentrations in serum from pregnant mothers and of outcomes in serum
from daughters at 15 years of age.
Analyte
In maternal serum
PFOSa (ng/mL)
PFOAa (ng/mL)
PFHxSa (ng/mL)
PFNAa (ng/mL)
In daughters’ serum
Total testosterone (nmol/L)
Sex hormone-binding globulin (nmol/L)

n

Minimum

25th

Median

75th

95th

Maximum

72
72
72
72

7.6
1.1
0.2
0.2

15.1
2.7
1.2
0.4

19.2
3.6
1.6
0.5

25.0
4.7
2.1
0.7

44.9
7.6
4.6
0.8

69.2
14.6
54.1
1.1

72
72

0.2
7.9

0.7
37.6

0.8
52.1

1.1
72.73

1.3
110.3

1.7
135.3

25th, 75th, and 95th are percentiles.
aLimits of detection are for PFOS 0.2 ng/mL, for PFOA and PFHxS 0.1 ng/mL, and for PFNA 0.082 ng/mL.

Environmental Health Perspectives •

volume

123 | number 12 | December 2015

with prenatal exposure in the upper tertile
compared with the group in the lower tertile
(Table 3). The parsimonious model for PFOA,
which was adjusted only by maternal education, showed similar results (β = 0.18; 95% CI:
0.01, 0.36) to those of the fully adjusted
model. The parsimonious model for PFHxS,
adjusted by maternal smoking during pregnancy, maternal age at delivery, and maternal
prepregnancy BMI, also showed similar results
(β = 0.20; 95% CI: 0.02, 0.38) to those of
the fully adjusted PFHxS model. In the fully
adjusted model, the difference in average
total testosterone concentrations in daughters
with prenatal PFNA concentrations in the
upper tertile compared with daughters with
prenatal PFNA in the lower tertile was smaller
(β = 0.05; 95% CI: –0.14, 0.24) than those
observed for other PFAAs. The PFNA parsimonious model (β = 0.10; 95% CI: –0.08, 0.28),
which was adjusted only for time of day when
daughter’s blood sample was obtained, showed
a somewhat higher average total testosterone
in daughters with prenatal PFNA in the upper
tertile compared with daughters with prenatal
PFNA in the lower tertile.
In separate regression models using
the same adjustment approach described
above (Table 3), we also explored associations of total testosterone concentrations in daughters with continuous prenatal
PFAAs. In fully adjusted models, differences in total testosterone concentrations
per nanogram per milliliter increase were
Table 2. Frequency distribution or means ± SDs
for study covariates.
Covariates
Total
Maternal covariates
Smoking during first trimester
Yes
No
Educational level
Lowest
Middle
Highest
Race
White
Age at delivery (years)
< 25
25–30
≥ 30
Prepregnancy body mass index (kg/m2)
Daughters’ covariates
Time of blood draw
0800–0900 hours
1200–1500 hours
Age at menarche (years)
< 12
12–13
14
BMI (kg/m2)
Menarcheal

n (%) or
mean ± SD
72 (100.0)
6 (8.3)
66 (91.7)
10 (13.9)
18 (25.0)
44 (61.1)
72 (100)
8 (11.1)
28 (38.9)
36 (50.0)
22.10 ± 3.27
37 (51.4)
35 (48.6)
4 (5.5)
57 (79.2)
11 (15.3)
21.14 ± 2.57
72 (100.0)

The mean age at menarche in the study group was
12.62 ± 0.90.

1327

Maisonet et al.

Discussion
We explored the influence of prenatal
exposure to PFOS, PFOA, PFHxS, and
PFNA on testosterone and SHBG serum
concentrations at 15 years of age in females.
In our study of 72 ALSPAC daughters,
prenatal exposure to PFOA, PFOS, and
PFHxS were associated with higher total
testosterone concentrations. To our knowledge, there is only one previous published
study where associations of prenatal PFOS
and PFOA with total testosterone and SHBG
concentrations were determined (Kristensen
et al. 2013). In this study, total testosterone
and SHBG were obtained at 20 years of
age in a sample of 75 female users of nonhormone contraceptives who were enrolled
in a population-based Danish cohort with
magnitude of exposure similar to that of
our study group. Kristensen et al. (2013)
constructed linear regression models using
continuous PFOS and PFOA exposure and
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1.8
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

wider confidence intervals. The regression
coefficient for the association with PFOA
(β = –0.003) was closer to the null than
the one in our study, and it also exhibited
wider confidence intervals. For SHBG, the
regression coefficients for the association with
PFOS (β = 0.006) and PFOA (β = 0.011)
in the study by Kristensen et al. (2013) were
close to the null compared with those in our

Testosterone and PFOS

Testosterone (nmol/L)

Testosterone (nmol/L)

natural log–transformed study outcomes,
adjusted by mother’s smoking and income,
and daughter’s smoking, BMI, luteinizing
and follicule-stimulating hormones, and
estradiol. For total testosterone, the regression coefficient for the association with PFOS
(β = 0.009) in the study by Kristensen et al.
(2013) appeared to be of similar magnitude
to that of our study, though it exhibited
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rather similar for PFOS (β = 0.006; 95% CI:
0.001, 0.012), PFOA (β = 0.033; 95% CI:
0.001, 0.066), and PFHxS (β = 0.003;
95% CI: –0.006, 0.012), compared with
differences in total testosterone concentrations
per nanogram per milliliter increase in PFNA
(β = 0.224; 95% CI: –0.089, 0.536). Overall,
results from fully adjusted models and from
parsimonious models were similar. After exclusions of influential data points, the difference
in total testosterone concentration per unit
increase in fully adjusted models for PFOS
was 0.009 (95% CI: 0.000, 0.018); PFOA
was 0.056 (95% CI: 0.000, 0.112); PFHxS
was 0.083 (95% CI: –0.016, 0.182); and
PFNA was 0.281 (95% CI: –0.011, 0.671).
Compared with results from models before
exclusion of influential data points, regression
coefficients were slightly larger.
In the fully adjusted models, SHBG
concentrations were on average higher in
daughters with prenatal PFOS (β = 3.46;
95% CI: –12.06, 18.98), PFOA (β = 5.02;
95% CI: –13.07, 23.11), and PFNA
(β = 7.91; 95% CI: –8.69, 24.52) concentrations in the upper tertile compared with
daughters with prenatal concentrations in the
lower tertile (Table 4). In contrast, SHBG
concentrations were on average lower in
daughters with prenatal PFOS (β = –2.86;
95% CI: –18.80, 13.09) and PFNA
(β = –4.53; 95% CI: –19.96, 10.90) in
the middle tertile compared with the lower
tertile in respective fully adjusted models. For
PFHxS (β = –5.3; 95% CI: –21.61, 11.00),
SHBG concentrations were on average lower
in the group of girls with prenatal concentrations in the upper tertile compared with those
in the lower tertile. Parsimonious models
showed rather similar results to those of their
respective fully adjusted models.
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Figure 1. Scatter plots for total testosterone concentrations in 15-year-old daughters by prenatal PFOS (A),
PFOA (B), PFHxS (C), and PFNA (D) serum concentrations with unadjusted linear regression line.
Table 3. Regression coefficients and 95% CIs from linear regression models for serum total testosterone
concentrations (nmol/L) in 15-year-old daughters by tertiles and continuous prenatal PFAAs.
Concentration
(ng/mL)
PFOS
≤ 15.8
15.9–22.6
> 22.6
Per 1 ng/mL
PFOA
≤ 2.9
2.9–4.1
> 4.1
Per 1 ng/mL
PFHxS
≤ 1.2
1.3–1.9
> 1.9
Per 1 ng/mL
PFNA
≤ 0.4
0.5–0.6
> 0.6
Per 1 ng/mL

Unadjusted
β (95% CI)

Fully adjusted
β (95% CI)a

Parsimonious
β (95% CI)b

0.76 ± 0.29
0.79 ± 0.26
0.97 ± 0.32

Reference
0.03 (–0.14, 0.20)
0.20 (0.03, 0.37)
0.008 (0.002, 0.014)

Reference
0.10 (–0.07, 0.28)
0.18 (0.01, 0.35)
0.006 (–0.001, 0.012)

Reference
0.03 (–0.14, 0.20)
0.20 (0.03, 0.37)
0.008 (0.002, 0.014)

24
24
24

0.74 ± 0.29
0.82 ± 0.32
0.96 ± 0.26

Reference
0.07 (–0.09, 0.24)
0.22 (0.05, 0.39)
0.037 (0.006, 0.068)

Reference
0.15 (–0.02, 0.32)
0.24 (0.05, 0.43)
0.033 (–0.001, 0.066)

Reference
0.10 (–0.07, 0.27)
0.18 (0.01, 0.36)
0.030 (–0.002, 0.061)

24
24
24

0.74 ± 0.31
0.83 ± 0.28
0.95 ± 0.29

Reference
0.10 (–0.07, 0.26)
0.21 (0.04, 0.38)
0.005 (–0.003, 0.014)

Reference
0.18 (0.00, 0.37)
0.18 (0.00, 0.35)
0.003 (–0.006, 0.012)

Reference
0.14 (–0.05, 0.33)
0.20 (0.02, 0.38)
0.005 (–0.004, 0.014)

26
25
21

0.81 ± 0.34
0.84 ± 0.30
0.88 ± 0.26

Reference
0.04 (–0.13, 0.21)
0.07 (–0.11, 0.25)
0.249 (–0.045, 0.543)

Reference
0.08 (–0.10, 0.25)
0.05 (–0.14, 0.24)
0.224 (–0.089, 0.536)

Reference
0.07 (–0.11, 0.24)
0.10 (–0.08, 0.28)
0.292 (–0.003, 0.586)

n

Mean ± SD

24
24
24

aEach

PFAA was modeled separately and adjusted by SHBG concentration, maternal education, maternal age at
delivery, maternal prepregnancy BMI, maternal smoking during pregnancy, time of day daughter’s blood sample was
obtained, daughter’s age at menarche, and daughter's BMI at 15 years. bEach PFAA was modeled separately and
adjusted only by those covariates associated with the corresponding PFAA at p < 0.20. Models were adjusted by PFOS,
none included; PFOA, maternal education; PFHxS, maternal smoking during pregnancy, maternal age at delivery, and
maternal prepregnancy BMI; PFNA, time of day daughter’s blood sample was obtained.
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study. Variations in covariates used in the
adjusted regression analyses and use of natural
log–transformed outcomes could explain the
differences between the results of Kristensen
et al. (2013) and our study.
Testosterone has been reported to exhibit
both circadian and menstrual cycle variation
(Ankarberg and Norjavaara 1999; Bui et al.
2013). These represent sources of random error
that could bias measures of association. We
used time of day the daughters’ blood sample
was drawn to explore circadian variation and
included this variable in the multivariate
regression analyses. We did not have information on the time of the menstrual cycle when
blood samples were obtained, so it remains a
potential source of variation in our study.
Testosterone circulates in the bloodstream mostly bound to SHBG (Davison and
Davis 2003). SHBG was not associated with
prenatal PFAA exposure in our study. Other
studies did not find associations between
SHBG and either prenatal or cross-sectional
exposure to PFAAs in male or female adolescents (Joensen et al. 2013; Kristensen et al.
2013; Vested et al. 2013). Although PFAAs
appear to have an affinity for SHBG binding
sites (Jones et al. 2003), it is not known
whether exposure to PFAAs could actually
alter circulating SHBG concentrations.
We did not find clear evidence of an
association of prenatal exposure to PFNA
with circulating testosterone concentrations.
Coefficients were close to the null for the tertile
estimates, but the coefficients for the continuous exposure were substantially larger than
for the other PFAAs, though much less precise.
We found that PFNA exhibited lower median
serum concentration and narrower IQR than
the other analytes tested. In a representative
sample of the U.S. population, PFNA levels
went up since the phaseout of PFOS in the
early 2000s (Kato et al. 2011), possibly because
it is used as a PFOS substitute. In our study,
serum samples were collected from pregnant
women before the phaseout of PFOS; thus
PFNA exposure levels are low compared
with more recent exposure levels seen in the
United States (Kato et al. 2011) and elsewhere
(Joensen et al. 2013).
Daughter’s BMI at 15 years and age
at menarche were introduced in the fully
adjusted regression models. If daughter’s BMI
at 15 years and age at menarche are actually
descendent of the study outcomes, their use
as a covariate in the model is unnecessary.
Neither daughter’s BMI at 15 years nor age
at menarche remained in the models adjusted
only by covariates that were associated with the
PFAA at p < 0.20. In addition to not having an
impact on precision, their exclusion from the
models did not appear to meaningfully change
the magnitude of the regression coefficients, so
it does not affect bias.
Environmental Health Perspectives •

volume

The mode of action through which prenatal
exposures to the PFAAs could alter testosterone
concentrations remains to be explained, but
may involve several pathways. One mode of
action could involve alterations in cholesterol metabolism through PPARα activation.
Alterations in the expression of genes associated
with lipid transport, lipoprotein metabolism,
and cholesterol biosynthesis in fetal livers of
mice prenatally exposed to PFOA, consistent
with PPARα activation, suggest opportunities
of fetal programming of PFOA (Rosen et al.
2007). Another mode of action could involve
activation of the PPARγ subtype. PPARγ is
believed to regulate energy homeostasis and
appears to be involved in fertility (Froment
et al. 2006). PPARγ is expressed in adipose
tissue, which is where conversion of about half
of the body’s circulating testosterone occurs.
Neither PFOS nor PFOA appears to increase
mouse or human liver PPARγ activity in a cell
assay study (Takacs and Abbott 2007). To
our knowledge, it is unclear whether prenatal
exposure to PFAA could alter adipose tissue
PPARγ activity. Exposure to the PFAAs was
not associated with menarche timing in our
study population (Christensen et al. 2011), but
it was inversely associated with birth weight
(Maisonet et al. 2012), and birth weight could
be regulated by PPAR activation. Last, other
modes of action could include increased levels
of gonadotropins (Vested et al. 2013) or
reduced conversion to estrogens.
Associations between PFAA exposure
and delayed menarche attainment observed
in longitudinal and cross-sectional epidemiologic studies (Kristensen et al. 2013; LopezEspinosa et al. 2011) and between PFAA
exposure and increased time to pregnancy and
irregular menstrual cycles (Fei et al. 2009) in

cross-sectional studies suggest that alterations
in testosterone levels may be a relevant mode
of action.
Our study is of an exploratory nature;
we answered the study questions using a
small group of enrolled cohort members
whose exposure and outcome data had been
collected for other purposes. Medians and
IQRs of exposure and outcome measures in
our study group were generally consistent
with the distribution of these variables in their
source samples (data not shown). Because we
excluded girls with early menarche attainment
from the analyses, selection bias could occur
if prenatal PFAAs exposure influences age at
menarche. In previous analysis, however, we
did not find clear evidence on an association
between prenatal PFAAs exposure and earlier
menarche attainment (Christensen et al.
2011). Analysis was conducted in a sample
of females because data on prenatal exposure
to PFAAs are not currently available for males
enrolled in the ALSPAC cohort; nonetheless, the exploration of associations between
prenatal exposures to PFAAs and hormones
levels in males is of scientific relevance.
Results of our study suggest a possibility
for fetal programming by prenatal PFAA
exposure. Besides the fetal stage, there are other
postnatal, developmental stages when hormone
production or signaling processes could be
vulnerable to effects of endocrine disruptors.
In addition, human exposure patterns to
PFAAs are changing on a global scale as a result
of changes in regulatory policies. To better
understand how endocrine disruptors alter
human reproduction, it would be valuable to
design epidemiologic studies with the capacity
to address multiple vulnerability periods and
time-varying exposures.

Table 4. Regression coefficients and 95% CIs from linear regression models for serum SHBG concentrations (nmol/L) in 15-year-old daughters by tertiles of prenatal PFAAs.
Concentration
(ng/mL)
PFOS
≤ 15.8
15.9–22.6
> 22.6
PFOA
≤ 2.9
2.9–4.1
> 4.1
PFHxS
≤ 1.2
1.3–1.9
> 1.9
PFNA
≤ 0.4
0.5–0.6
> 0.6

n

Mean ± SD

Unadjusted
β (95% CI)

Fully adjusted
β (95% CI)a

Parsimonious
β (95% CI)b

24
24
24

56.71 ± 30.42
54.31 ± 25.15
59.29 ± 25.40

Reference
–2.40 (–18.01, 13.20)
2.58 (–13.02, 18.19)

Reference
–2.86 (–18.80, 13.09)
3.46 (–12.06, 18.98)

Reference
–2.40 (–18.01, 13.20)
2.58 (–13.02, 18.19)

24
24
24

55.77 ± 33.50
60.24 ± 26.07
54.30 ± 19.85

Reference
4.47 (–11.11, 20.05)
–1.47 (–17.06, 14.11)

Reference
0.32 (–15.97, 16.61)
5.02 (–13.07, 23.11)

Reference
3.83 (–11.54, 19.19)
5.45 (–10.50, 21.40)

24
24
24

57.87 ± 33.09
60.61 ± 24.19
51.82 ± 22.23

Reference
2.74 (–12.76, 18.25)
–6.05 (–21.55, 9.45)

Reference
–2.22 (–19.62, 15.19)
–5.31 (–21.61, 11.00)

Reference
0.04 (–17.17, 17.24)
–6.40 (–23.01, 10.21)

26
25
21

57.90 ± 27.50
51.75 ± 25.59
61.34 ± 27.62

Reference
–6.15 (–21.17, 8.88)
3.44 (–12.29, 19.18)

Reference
–4.53 (–19.96, 10.90)
7.91 (–8.69, 24.52)

Reference
–5.15 (–20.61, 10.32)
4.52 (–11.70, 20.73)

aEach

PFAA was modeled separately and adjusted by maternal education, maternal age at delivery, maternal prepregnancy BMI, maternal smoking during pregnancy, time of day daughter’s blood sample was obtained, daughter’s age at
menarche, and daughter BMI at 15 years. bEach PFAA was modeled separately and adjusted only by those covariates
associated with the corresponding PFAA at p < 0.20. Models were adjusted by PFOS, none included; PFOA, maternal
education; PFHxS, maternal smoking during pregnancy, maternal age at delivery, and maternal prepregnancy BMI;
PFNA, time of day daughter’s blood sample was obtained.
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